AAAAAA

   
Results: 1-13 |
Results: 13
RANDOMIZED STUDY OF PACLITAXEL-CISPLATIN VERSUS CISPLATIN-TENIPOSIDE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER
Authors: GIACCONE G SPLINTER TAW DEBRUYNE C KHO GS LIANES P VANZANDWIJK N PENNUCCI MC SCAGLIOTTI G VANMEERBEECK J VANHOESEL Q CURRAN D SAHMOUD T POSTMUS PE
Citation: G. Giaccone et al., RANDOMIZED STUDY OF PACLITAXEL-CISPLATIN VERSUS CISPLATIN-TENIPOSIDE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER, Journal of clinical oncology, 16(6), 1998, pp. 2133-2141
MANAGEMENT OF MALIGNANT PLEURAL EFFUSIONS
Authors: GROSSI F PENNUCCI MC TIXI L CAFFERATA MA ARDIZZONI A
Citation: F. Grossi et al., MANAGEMENT OF MALIGNANT PLEURAL EFFUSIONS, Drugs, 55(1), 1998, pp. 47-58
CISPLATIN-VINDESINE-MITOMYCIN (MVP) VS CISPLATIN-IFOSFAMIDE-VINORELBINE (PIN) VS CARBOPLATIN-VINORELBINE (CAN) IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER (NSCLC) - A FONICAP RANDOMIZED PHASE-II STUDY
Authors: BALDINI E TIBALDI C ARDIZZONI A SALVATI F ANTILLI A PORTALONE L BARBERA S ROMANO F DEMARINIS F MIGLIORINO MR NOSEDA MA BORGHINI U CRIPPA M FERRARA G RAIMONDI M FIORETTI M BANDERA M PENNUCCI MC GALEASSO G CACCIANI GC LEPIDINI G SUNSERI G LANFRANCO C RINALDI M LIONETTO R CONTE PF ROSSO R
Citation: E. Baldini et al., CISPLATIN-VINDESINE-MITOMYCIN (MVP) VS CISPLATIN-IFOSFAMIDE-VINORELBINE (PIN) VS CARBOPLATIN-VINORELBINE (CAN) IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER (NSCLC) - A FONICAP RANDOMIZED PHASE-II STUDY, British Journal of Cancer, 77(12), 1998, pp. 2367-2370
ANALYSIS OF K-RAS, P53, BCL-2 AND RB EXPRESSION IN NONSMALL CELL LUNG-CANCER CELL-LINES
Authors: LOPREVITE M VARESCO L FAVONI R FERRARA GB MORO F OTTAGGIO L FRONZA G CAMPOMENOSI P ABBONDANDOLO A CUTRONA G RONCELLA S ALBINI A ALUIGI MG POZZI S PERA C BITICCHI R GISMONDI V GROSSI F PENNUCCI MC ARDIZZONI A
Citation: M. Loprevite et al., ANALYSIS OF K-RAS, P53, BCL-2 AND RB EXPRESSION IN NONSMALL CELL LUNG-CANCER CELL-LINES, International journal of oncology, 11(6), 1997, pp. 1203-1208
PHASE-II STUDY OF INDUCTION CHEMOTHERAPY FOLLOWED BY RADIOTHERAPY COMBINED WITH DAILY CISPLATIN IN STAGE-III INOPERABLE NONSMALL CELL LUNG-CANCER (NSCLC)
Authors: SCOLARO T ARDIZZONI A GIUDICI S GROSSI F COSSO M PENNUCCI MC BACIGALUPO A ROSSO R VITALE V
Citation: T. Scolaro et al., PHASE-II STUDY OF INDUCTION CHEMOTHERAPY FOLLOWED BY RADIOTHERAPY COMBINED WITH DAILY CISPLATIN IN STAGE-III INOPERABLE NONSMALL CELL LUNG-CANCER (NSCLC), International journal of radiation oncology, biology, physics, 39(2), 1997, pp. 313-313
COMBINED CISPLATIN, DOXORUBICIN, AND MITOMYCIN FOR THE TREATMENT OF ADVANCED PLEURAL MESOTHELIOMA - A PHASE-II FONICAP TRIAL
Authors: PENNUCCI MC ARDIZZONI A PRONZATO P FIORETTI M LANFRANCO C VERNA A GIORGI G VIGANI A FROLA C ROSSO R
Citation: Mc. Pennucci et al., COMBINED CISPLATIN, DOXORUBICIN, AND MITOMYCIN FOR THE TREATMENT OF ADVANCED PLEURAL MESOTHELIOMA - A PHASE-II FONICAP TRIAL, Cancer, 79(10), 1997, pp. 1897-1902
PHASE-I STUDY OF SIMULTANEOUS DOSE-ESCALATION AND SCHEDULE ACCELERATION OF CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE USING GRANULOCYTE-COLONY-STIMULATING FACTOR WITH OR WITHOUT ANTIMICROBIAL PROPHYLAXIS IN PATIENTS WITH SMALL-CELL LUNG-CANCER
Authors: ARDIZZONI A PENNUCCI MC DANOVA M VISCOLI C MARIANI GL GIORGI G VENTURINI M MEREU C SCOLARO T ROSSO R
Citation: A. Ardizzoni et al., PHASE-I STUDY OF SIMULTANEOUS DOSE-ESCALATION AND SCHEDULE ACCELERATION OF CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE USING GRANULOCYTE-COLONY-STIMULATING FACTOR WITH OR WITHOUT ANTIMICROBIAL PROPHYLAXIS IN PATIENTS WITH SMALL-CELL LUNG-CANCER, British Journal of Cancer, 74(7), 1996, pp. 1141-1147
PACLITAXEL FOR MALIGNANT PLEURAL MESOTHELIOMA - A PHASE-II STUDY OF THE EORTC LUNG-CANCER COOPERATIVE GROUP
Authors: VANMEERBEECK J DEBRUYNE C VANZANDWIJK N POSTMUS PE PENNUCCI MC VANBREUKELEN F GALDERMANS D GROEN H PINSON P VANGLABBEKE M VANMARCK E GIACCONE G
Citation: J. Vanmeerbeeck et al., PACLITAXEL FOR MALIGNANT PLEURAL MESOTHELIOMA - A PHASE-II STUDY OF THE EORTC LUNG-CANCER COOPERATIVE GROUP, British Journal of Cancer, 74(6), 1996, pp. 961-963
CISPLATIN, VINDESINE, MITOMYCIN (MVP) VS CISPLATIN, IFOSFAMIDE, NAVELBINE (PIN) VS CARBOPLATIN, NAVELBINE (CAN) IN ADVANCED NON-SMALL-CELL LUNG-CANCER (NSCLC)
Authors: BALDINI E PORTALONE L DEMARINIS F BARBERA S ARDIZZONI A PENNUCCI MC RAIMONDI M CONTE PF SALVATI F CAFFERATA MA SORESI E PORCILE GF TESTORE F RIMOLDI R BANDERA M DIROSA T RINALDI M LIONETTO R ROSSO R
Citation: E. Baldini et al., CISPLATIN, VINDESINE, MITOMYCIN (MVP) VS CISPLATIN, IFOSFAMIDE, NAVELBINE (PIN) VS CARBOPLATIN, NAVELBINE (CAN) IN ADVANCED NON-SMALL-CELL LUNG-CANCER (NSCLC), European journal of cancer, 31A, 1995, pp. 1059-1059
MITOMYCIN-IFOSFAMIDE-CISPLATINUM (MIP) VS MIP-INTERFERON VS CISPLATINUM-CARBOPLATIN IN METASTATIC NON-SMALL-CELL LUNG-CANCER - A FONICAP RANDOMIZED PHASE-II STUDY
Authors: ARDIZZONI A ADDAMO GF BALDINI E BORGHINI U PORTALONE L DEMARINIS F LIONETTO R CONTE PF BRUZZI P PENNUCCI MC VENTURINI M RINALDI M ROSSO R SALVATI F
Citation: A. Ardizzoni et al., MITOMYCIN-IFOSFAMIDE-CISPLATINUM (MIP) VS MIP-INTERFERON VS CISPLATINUM-CARBOPLATIN IN METASTATIC NON-SMALL-CELL LUNG-CANCER - A FONICAP RANDOMIZED PHASE-II STUDY, British Journal of Cancer, 71(1), 1995, pp. 115-119
RECOMBINANT INTERFERON-ALPHA-2B IN THE TREATMENT OF DIFFUSE MALIGNANTPLEURAL MESOTHELIOMA
Authors: ARDIZZONI A PENNUCCI MC CASTAGNETO B MARIANI GL CINQUEGRANA A MAGRI D VERNA A SALVATI F ROSSO R
Citation: A. Ardizzoni et al., RECOMBINANT INTERFERON-ALPHA-2B IN THE TREATMENT OF DIFFUSE MALIGNANTPLEURAL MESOTHELIOMA, American journal of clinical oncology, 17(1), 1994, pp. 80-82
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) ALLOWS ACCELERATION AND DOSE INTENSITY INCREASE OF CEF CHEMOTHERAPY - A RANDOMIZED STUDY IN PATIENTS WITH ADVANCED BREAST-CANCER
Authors: ARDIZZONI A VENTURINI M SERTOLI MR GIANNESSI PG BREMA F DANOVA M TESTORE F MARIANI GL PENNUCCI MC QUEIROLO P SILVESTRO S BRUZZI P LIONETTO R LATINI F ROSSO R
Citation: A. Ardizzoni et al., GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) ALLOWS ACCELERATION AND DOSE INTENSITY INCREASE OF CEF CHEMOTHERAPY - A RANDOMIZED STUDY IN PATIENTS WITH ADVANCED BREAST-CANCER, British Journal of Cancer, 69(2), 1994, pp. 385-391
COMBINATION OF CHEMOTHERAPY AND RECOMBINANT ALPHA-INTERFERON IN ADVANCED NONSMALL CELL LUNG-CANCER - MULTICENTRIC RANDOMIZED FONICAP TRIAL REPORT
Authors: ARDIZZONI A SALVATI F ROSSO R BRUZZI P RUBAGOTTI A PENNUCCI MC MARIANI GL DEMARINIS F PALLOTTA G ANTILLI A CRUCIANI AM RINALDI M TONACHELLA R FIORETTI M BARBERA S MANTELLINI E SORESI E PASTORINO G BELLI M FERRARA G VENTURINI M SCAGLIOTTI G SANTI L PORTALONE L CRIPPA M BORGHINI U BREMA F RIMOLDI R BANDERA M PIACENZA G ROMANO F COLANTUONI G BONSIGNORE G EPIS R ANDREOLA E SCAGLIOTTI E POZZI E BOTTA M CASTAGNETO B LANFRANCO C TESTORE F LUPPIS B DEPALMA M ROCCHI D BARACCO F CINQUEGRANA A RASO C BONAVIA M ROPOLO F
Citation: A. Ardizzoni et al., COMBINATION OF CHEMOTHERAPY AND RECOMBINANT ALPHA-INTERFERON IN ADVANCED NONSMALL CELL LUNG-CANCER - MULTICENTRIC RANDOMIZED FONICAP TRIAL REPORT, Cancer, 72(10), 1993, pp. 2929-2935
Risultati: 1-13 |